Cargando…

Circulating Biomarkers for Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is the most common form of muscular dystrophy. Genetic and biochemical research over the years has characterized the cause, pathophysiology and development of the disease providing several potential therapeutic targets and/or biomarkers. High throughput – omic technologie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aartsma-Rus, Annemieke, Spitali, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271432/ https://www.ncbi.nlm.nih.gov/pubmed/27858763 http://dx.doi.org/10.3233/JND-150102

Ejemplares similares

Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)

Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models
por: Heezen, L.G.M., et al.
Publicado: (2023)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East
por: Alghamdi, Fouad, et al.
Publicado: (2021)

CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
por: Chey, Yu C. J., et al.
Publicado: (2022)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy
por: van Putten, Maaike, et al.
Publicado: (2019)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy
por: Kogelman, Bauke, et al.
Publicado: (2018)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Cross‐sectional serum metabolomic study of multiple forms of muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2018)

TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2020)

Cardiac MRI biomarkers for Duchenne muscular dystrophy
por: Magrath, Patrick, et al.
Publicado: (2018)

A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Clinical utility of serum biomarkers in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2016)

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E.C., et al.
Publicado: (2021)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
por: Jirka, Silvana M.G., et al.
Publicado: (2018)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021)

Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress
por: Grounds, Miranda D., et al.
Publicado: (2020)

Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions
por: Fortunato, Fernanda, et al.
Publicado: (2023)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_opiaq4jc34l368lveeapd4ukco